Biography
Dr. Velculescu led the first genome wide sequence analysis in human cancers, identifying key genes and pathways dysregulated in tumorigenesis. He developed methods for global gene expression analyses and coined the word transcriptome" to describe the patterns that could now be obtained in cancer and other cells. These analyses identified a variety of genes not previously known to be involved in neoplasia, including PIK3CA as one of the most highly mutated genes in human cancer. His team's discoveries have led to new FDA approved therapies against PI3K and IDH1, and diagnostic tests for comprehensive tumor profiling. More recently, his group has created noninvasive machine learning liquid biopsy approaches for early detection and monitoring of cancer patients. His work has provided new paradigms for understanding human cancer that have benefited patients worldwide. He has been a Founder and CoCEO of Personal Genome Diagnostics and is Founder and CEO of Delfi Diagnostics.